

Disclosures

Personal Commercial (5)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|--|-------------------------------|---|
| <i>Self</i> | | | |
| Amgen Inc. | Stock | Significant (\geq \$5,000) | <i>Other</i> |
| Edgewise Therapeutics, Inc. | Other - <i>Scientific Advisory Board</i> | Modest ($<$ \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Lexicon Pharmaceuticals, Inc. | Other - <i>Scientific Advisory Board</i> | Modest ($<$ \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Sardocor Corp. | Consultant Fees/Honoraria | Significant (\geq \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Space Exploration Technologies Corp.; aka, SpaceX | Other - <i>Medical Advisor</i> | Modest ($<$ \$5,000) | <i>Other</i> |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

| Year | Case Title | Represented | Description | Compensation |
|-------------|---|---|---|-----------------------|
| <i>Self</i> | | | | |
| 2023 | 17-year old patient with hypertrophic cardiomyopathy who suffered sudden cardiac death. | Defendant † <i>Aaronson Rappaport Feinstein & Deutsch, LLP</i> | Provide record review and expert testimony if required on behalf of defendant (Dr. Ethan Rowin) and co-defendant (Atlantic Health System Hospital/Morristown Medical Center). | Modest ($<$ \$5,000) |

† *Commercial Funding Source* | ‡ *Trial Name*

Agreement

Certified Education Attestation | Signed on 4/8/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 4/8/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 4/8/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 4/8/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.

